Approaches towards individualized immune intervention

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 45-50

  Giese, Thomas ^a   Sommerer, Claudia ^a   Zeier, Martin ^a   Meuer, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Cyclosporin A; Immunosuppression; Transplantation; Viral infection

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT;

AREA UNDER THE CURVE; BASAL CELL CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED CANCER; DRUG MECHANISM; ENZYME INHIBITION; FUNCTIONAL STATUS; GRAFT SURVIVAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LOW DRUG DOSE; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

ANIMALS; CALCINEURIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; TRANSPLANTATION;

EID: 77952571260     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282063     Document Type: Review

References (56)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-612.
2. Wong G, Chapman JR: Cancers after renal transplantation. Transplant Rev (Orlando) 2008;22:141-149.
3. - 2007 OPTN/SRTR Annual Report 1997-2006. HHS/HRSA/HSB/DOT;available at http://www.ustransplant.org/annual-reports.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack ofimprovement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-383.
5. Howard RJ, Patton PR, Reed AI, Hemming AW, Van der Werf WJ, Pfaff WW, Srinivas TR, Scornik JC: The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923-1928.
6. Buell JF, Gross TG, Woodle ES: Malignancy after transplantation. Transplantation 2005;80(suppl 2):S254-S264.
7. Dantal J, Pohanka E: Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22(suppl 1): i4-i10.
8. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582-1588.
9. Lutz J, Heemann U: Tumours after kidney transplantation. Curr Opin Urol 2003;13:105-109.
10. Buell JF, Hanaway MJ, Trofe J, Gross TG, Beebe TM, Alloway RR, First M, Woodle ES: De novo breast cancer in renal transplant recipients. Transplant Proc 2002;34:1778-1779.
11. Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES: De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005;37:960-961.
12. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628. (Pubitemid 28098444)
13. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthan-thiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-534.
14. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S: Over-expression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res 2008;68:5689-5698.
15. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B: Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006;81:1227-1233.
16. Koehl GE, Andrassy J, Guba M, et al: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004;77:1319-1326.
17. Gutierrez-Dalmau A, Campistol JM: The role of proliferation signal in hibitors in post-transplant malignancies. Nephrol Dial Transplant 2007;22(suppl 1):i11-i16.
18. Campistol JM, Albanell J, Arns W, et al: Use of proliferation signal inhibitors in the management of post-transplant malignancies - clinical guidance. Nephrol Dial Transplant 2007;22(suppl 1):i36-i41.
19. Stallone G, Schena A, Infante B, et al: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323.
20. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF: Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-2244.
21. Frost P, Shi Y, Hoang B, Lichtenstein A: AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007;26:2255-2262.
22. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF: Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007;49:462-470.
23. Goudar RK, Shi Q, Hjelmeland MD, et al: Combination therapy ofinhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101-112.
24. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Gibbons J, Lichtenstein A: In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104:4181-4187.
25. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance immuno-suppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-889.
26. Campistol JM, Eris J, Oberbauer R, et al: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-589.
27. Pascual J: Post-transplant lymphoproliferative disorder - the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007;22(suppl 1):i27-i35. (Pubitemid 47073742)
28. Ekberg H, Tedesco-Silva H, Demirbas A, et al: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-2575.
29. Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE: Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 1968;278:479-483.
30. Matter B, Zukoski CF, Killen DA, Ginn E: Transplanted carcinoma in an immunosup-pressed patient. Transplantation 1970;9:71-74.
31. Morath C, Rohmeiss P, Schwenger V, et al: Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearingal lograft. Transplantation 2005;80:540-542.
32. Starzl TE, Nalesnik MA, Porter KA, et al: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
33. Wijnveen AC, Persson H, Bjorck S, Blohme I: Disseminated Kaposi's sarcoma - full regression after withdrawal ofimmunosup-pressive therapy: report of a case. Transplant Proc 1987;19:3735-3736.
34. Duman S, Toz H, Asci G, et al: Successful treatment of post-transplant Kaposi's sarcoma by reduction ofimmunosuppression. Nephrol Dial Transplant 2002;17:892-896.
35. Friedlaender MM, Rubinger D, Rosenbaum E, Amir G, Siguencia E: Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 2002;73:1849-1850.
36. Otley CC, Coldiron BM, Stasko T, Goldman GD: Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-463.
37. Chuang FR, Hsieh H, Hsu KT, Huang HF: Increasing transplant cancer patient survival by conversion ofimmunosuppressive agents. Transplant Proc 1996;28:1346-1347.
38. Kahan BD: Cyclosporine. N Engl J Med 1989;321:1725-1738.
39. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT: Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996;62:599-606.
40. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH: Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002;24:479-486.
41. Oellerich M, Armstrong VW: Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002;24:40-46.
42. Thervet E, Pfeffer P, Scolari MP, et al: Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003;76:903-908.
43. Midtvedt K, Fauchald P, Bergan S, et al: C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003;76:1236-1238.
44. Einecke G, Mai I, Fritsche L, Slowinski T, Waiser J, Neumayer HH, Budde K: The value of C2 monitoring in stable renalal lograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 2004;19:215-222.
45. Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, Buechler M, Meuer S: Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004;77:339-344.
46. Giese T, Zeier M, Meuer S: Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004;19(suppl 4):IV55-IV60.
47. Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, Zeier M, Giese T: Pharmacodynamic monitoring of cyclosporine A in renal allograft recipients shows a quantitative relationship between immunosup-pression and the occurrence of recurrent infections and malignancies. Transplantation 2006;82:1280-1285.
48. Stein CM, Murray JJ, Wood AJ: Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclo-sporine effect. Clin Chem 1999;45:1477-1484.
49. Härtel C, Fricke L, Schumacher N, Kirchner H, Müller-Steinhardt M: Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem 2002;48:2225-2231.
50. Halloran PF, Helms LM, Kung L, Noujaim J: The temporal profile of calcineurin inhibition by cyclosporine in vivo. Tra nspla ntation 1999;68:1356-1361.
51. van Rossum HH, Romijn FP, Sellar KJ, Smit NP, van der Boog PJ, de Fijter JW, van Pelt J: Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin Chem 2008;54:517-524.
52. Sottong PR, Rosebrock JA, Britz JA, Kramer TR: Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000;7:307-311.
53. Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, Jauch KW, Guba M: The janus face ofimmunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007;71:1271-1278.
54. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T: Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008;22:549-554.
55. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M: Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept ofindividual immunosuppression. Tra nsplantation 2008;85:15-21.
56. Collaborative Transplant Study. http://www. ctstransplant.org/public/ graphics/archive.shtml.